Thermo Fisher Scientific Partners with Datavant to Enhance Real-World Data Connectivity in Clinical Research
核心洞察
Thermo Fisher Scientific (搜索) announced a strategic collaboration with Datavant (搜索) to integrate privacy-preserving tokenization technology across its PPD clinical research business, enabling secure linkage of patient-level data from over 350 real-world data partners and 80,000 US hospitals and clinics.
The partnership aims to enhance real-world data enrichment of randomized clinical trials and improve connectivity across PPD CorEvitas (搜索) Clinical Registries and PPD Evidera (搜索) solutions through encrypted tokenization and secure data linkage capabilities.
The collaboration is designed to help pharmaceutical and biotech sponsors generate stronger evidence faster by providing enhanced linked patient data and advanced analytics to improve study design, patient recruitment strategies, and accelerate evidence generation.
Thermo Fisher Scientific (搜索) has entered into a strategic data collaboration with Datavant (搜索) aimed at expanding real-world data (RWD) interoperability and linkage across clinical research and development programs. The partnership integrates Datavant's privacy-preserving tokenization technology into Thermo Fisher's PPD clinical research business to enable secure linkage and analysis of patient-level data.
Enhanced Data Connectivity Across Healthcare Ecosystem
Datavant (搜索)'s platform supports encrypted tokenization and linkage of de-identified datasets across a broad healthcare ecosystem that includes more than 350 real-world data partners and 80,000 US hospitals and clinics. By embedding this technology within Thermo Fisher's RWD infrastructure, the companies aim to allow pharmaceutical and biotech sponsors to securely connect research datasets and retrieve consented electronic medical record data for bespoke real-world evidence (RWE) generation.
The collaboration spans RWD enrichment of randomized clinical trials as well as integration across PPD CorEvitas (搜索) Clinical Registries and PPD Evidera (搜索) solutions. The integration is intended to provide sponsors with enhanced linked patient data and advanced analytics capabilities to design more connected studies, improve patient recruitment strategies, and accelerate evidence generation.
"Data interoperability is critical to the next generation of evidence generation," said Karen Kaucic, MD, president, patient and advisory services, and chief medical officer, clinical research, Thermo Fisher Scientific (搜索). "By enabling privacy-protected data connectivity at scale, this collaboration allows us to deliver a more seamless and efficient research experience for our customers."
Privacy-Protected Research Capabilities
The partnership enables secure RWE generation by combining Datavant (搜索)'s tokenization technology with Thermo Fisher's clinical research infrastructure and therapeutic expertise. The companies aim to bring richer, more connected patient datasets into the research process while maintaining compliance and data protection safeguards.
According to the companies, enabling privacy-protected data connectivity at scale can reduce operational friction across the research lifecycle, from clinical trials through observational and post-market studies.
"This collaboration with Thermo Fisher underscores Datavant (搜索)'s role in enabling secure, privacy-preserving data connectivity at scale," said Arnaub Chatterjee, GM and president of life sciences at Datavant. "By combining Datavant's trusted data linkage technology with Thermo Fisher's deep clinical research expertise and infrastructure, we're helping bring richer, more connected patient data into the research process."
Digital Transformation Strategy
Krishna Cheriath, vice president and head of digital and artificial intelligence (AI), biopharma services at Thermo Fisher Scientific (搜索), described the agreement as part of the company's broader digital transformation strategy. "By integrating Datavant (搜索)'s capabilities with Thermo Fisher's data, digital and AI capabilities, we can help our customers accelerate insights and ultimately improve patient outcomes," he said.
The collaboration further strengthens Thermo Fisher's position in RWE, registry, and observational study services, complementing ongoing investments in digital tools designed to modernize how data and AI are applied across drug development. These investments include a recent collaboration with OpenAI (搜索), where Thermo Fisher integrated OpenAI APIs into its Accelerator Drug Development platform and broader operations.
Within the PPD clinical research business, OpenAI (搜索) capabilities are being applied with the goal of shortening clinical trial timelines and improving development decision-making. The integration also includes efforts to leverage AI to identify therapies less likely to succeed earlier in development, enabling sponsors to reallocate resources toward higher-potential candidates.
Addressing Market Evolution
The partnership addresses rapidly changing market conditions in clinical data management. As Luke Wilson, senior director, biotech, pharma services at Thermo Fisher, highlighted in discussions about real-time data visibility in clinical trials: "The market is changing rapidly in front of us. If you think about how data is captured—how data is managed within certain regions and even therapeutic areas—it's really important that we remove some of those silos to enable data to be captured and logged in an appropriate way that then can be provided to the sponsor."
The collaboration represents another milestone in Thermo Fisher's continued investment in digital transformation to accelerate innovation for customers, with the ultimate goal of supporting better patient outcomes through more efficient and connected research processes.